[1] Choy, E. H. S., & Calabrese, L. H. (2018). Neuroendocrine and neurophysiological effects of interleukin 6 in rheumatoid arthritis. Rheumatology (United Kingdom), 57(11), 1885–1895. https://doi.org/10.1093/rheumatology/kex391
[2] Bullock, J., Rizvi, S. A. A., Saleh, A. M., Ahmed, S. S., Do, D. P., Ansari, R. A., & Ahmed, J. (2019). Rheumatoid arthritis: A brief overview of the treatment. Medical Principles and Practice, 27(6), 501–507. https://doi.org/10.1159/000493390
[3] Deane, K. D., & Holers, V. M. (2019). The Natural History of Rheumatoid Arthritis. Clinical Therapeutics, 41(7), 1256–1269. https://doi.org/10.1016/j.clinthera.2019.04.028.
[4] Drake, D. A. R., Chan, F. T., Briski, E., Bailey, S. A., & Macisaac, H. J. (2018). Extra-articular rheumatoid arthritis. Reumatismo, 73(4), 112–119.
[5] Gavrilă, B. I., Ciofu, C., & Stoica, V. (2016). Biomarkers in Rheumatoid Arthritis, what is new? Journal of Medicine and Life, 9(2), 144–148.
[6] Aviña-Zubieta, J. A., Choi, H. K., Sadatsafavi, M., Etminan, M., Esdaile, J. M., & Lacaille, D. (2008). Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Care and Research, 59(12), 1690–1697. https://doi.org/10.1002/art.24092
[7] Ali, E. T., Jabbar, A. S., & Mohammed, A. N. (2019). A Comparative Study of Interleukin 6, Inflammatory Markers, Ferritin, and Hematological Profile in Rheumatoid Arthritis Patients with Anemia of Chronic Disease and Iron Deficiency Anemia. Anemia, 2019. https://doi.org/10.1155/2019/3457347
[8] Robertson, J., Peters, M. J., McInnes, I. B., & Sattar, N. (2013). Changes in lipid levels with inflammation and therapy in RA: A maturing paradigm. Nature Reviews Rheumatology, 9(9), 513–523. https://doi.org/10.1038/nrrheum.2013.91
[9] van Sijl, A. M., Peters, M. J. L., Knol, D. L., de Vet, R. H. C., Sattar, N., Dijkmans, B. A. C., Smulders, Y. M., & Nurmohamed, M. T. (2011). The Effect of TNF-alpha Blocking Therapy on Lipid Levels in Rheumatoid Arthritis: A Meta-Analysis. Seminars in Arthritis and Rheumatism, 41(3), 393–400. https://doi.org/10.1016/j.semarthrit.2011.04.003
[10] Wan, X., Wang, W., Liu, J., & Tong, T. (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Medical Research Methodology, 14(1), 1–13. https://doi.org/10.1186/1471-2288-14-135
[11] DeBose-Boyd, R. A. (2018). Significance and regulation of lipid metabolism. Seminars in Cell and Developmental Biology, 81, 97. https://doi.org/10.1016/j.semcdb.2017.12.003
[12] Venetsanopoulou, A. I., Pelechas, E., Voulgari, P. V., & Drosos, A. A. (2020). The lipid paradox in rheumatoid arthritis: the dark horse of the augmented cardiovascular risk. Rheumatology International, 40(8), 1181–1191. https://doi.org/10.1007/s00296-020-04616-2
[13] Naseri, H., Zarrin, R., Ayremlou, P., Aghdashi, M. A., & Seyedmardani, S. (2020). Evaluating the relationship between dietary intake with inflammatory factors, lipid profile and clinical symptoms in patients with rheumatoid arthritis. Clinical Nutrition ESPEN, 40(xxxx), 138–143. https://doi.org/10.1016/j.clnesp.2020.09.215
[14] Svenson, K. L. G., Lithell, H., Hällgren, R., Selinus, I., & Vessby, B. (1987). Serum Lipoprotein in Active Rheumatoid Arthritis and Other Chronic Inflammatory Arthritides: I. Relativity to Inflammatory Activity. Archives of Internal Medicine, 147(11), 1912–1916. https://doi.org/10.1001/archinte.1987.00370110040005
[15] Lazarevic, M. B., Vitic, J., Mladenovic, V., Lee Myones, B., Skosey, J. L., & Swedler, W. I. (1992). Dyslipoproteinemia in the course of active rheumatoid arthritis. Seminars in Arthritis and Rheumatism, 22(3), 172–180. https://doi.org/10.1016/0049-0172(92)90017-8
[16] Rantapaa-dahlqvist, S., Wallberg-jonsson, S., & Dahlen, G. (1991). Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Cv, 366–368.
[17] Curtis, J. R., John, A., & Baser, O. (2012). Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy. Arthritis Care and Research, 64(9), 1282–1291. https://doi.org/10.1002/acr.21693
[18] Vinapamula, K. S., Manohar, S. M., Bitla, A. R., Kanduri, R., Bhattaram, S. K., & Pemmaraju, S. R. V. L. N. (2013). Evaluation of dyslipidaemia in patients with rheumatoid arthritis in South Indian population. Indian Journal of Rheumatology, 8(4), 155–160. https://doi.org/10.1016/j.injr.2013.06.006
[19] van den Oever, I. A. M., Baniaamam, M., Simsek, S., Raterman, H. G., van Denderen, J. C., van Eijk, I. C., Peters, M. J. L., van der Horst-Bruinsma, I. E., Smulders, Y. M., & Nurmohamed, M. T. (2021). The effect of anti-TNF treatment on body composition and insulin resistance in patients with rheumatoid arthritis. Rheumatology International, 41(2), 319–328. https://doi.org/10.1007/s00296-020-04666-6
[20] Dursunoǧlu, D., Evrengül, H., Polat, B., Tanriverdi, H., Çobankara, V., Kaftan, A., & Kiliç, M. (2005). Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: Serum levels and relationship to inflammation. Rheumatology International, 25(4), 241–245. https://doi.org/10.1007/s00296-004-0438-0
[21] Yoo, W.-H. (2004). Dyslipoproteinemia in patients with active rheumatoid arthritis: effects of disease activity, sex, and menopausal status on lipid profiles. The Journal of Rheumatology, 31(9), 1746 LP – 1753. http://www.jrheum.org/content/31/9/1746.abstract
[22] Chen, D.-Y., Chen, Y.-M., Hsieh, T.-Y., Hsieh, C.-W., Lin, C.-C., & Lan, J.-L. (2015). Significant effects of biologic therapy on lipid profiles and insulin resistance in patients with rheumatoid arthritis. Arthritis Research & Therapy, 17, 1–13.
[23] Mahdi, E. A., Mohamed, L. A., & Hadi, M. A. (2012). The Relationship Between Lipid Profile and Inflammatory Markers. Iraqi National Journal of Chemistry, 47, 391– 400.